Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Listed
Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,388 across all filing types
Latest filing 2026-06-22 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2616 · 5 venues

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and concerns changes in issued shares, treasury shares, and share repurchases by CStone Pharmaceuticals. It provides detailed data on share repurchases and treasury shares transactions, including trading dates, prices, and aggregated totals. There is no indication of it being a full annual or quarterly financial report, earnings release, or other regulatory filings like management changes or legal proceedings. The focus is clearly on share repurchase activities and changes in capital structure. This matches the description for 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length and coverage confirm it is a full report on such transactions rather than a brief announcement or certificate.
2026-06-22 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to 'changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares' for CStone Pharmaceuticals. It details specific repurchase transactions, including number of shares repurchased, prices, and dates, and confirms adherence to exchange rules. There is no mention of annual or quarterly financial results, no narrative management discussion, no earnings highlights, no voting results, or other types of governance or legal content. The focus is specifically on reporting share repurchase activities and changes in share capital. This matches the description of 'Transaction in Own Shares' (Code: POS), which covers company buying back or selling its own shares (share repurchase/issuance). The document length is 9267 characters indicating it is a detailed disclosure, not a brief notice or announcement alone. Therefore, the classification is POS with high confidence.
2026-06-18 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return filed by an equity issuer, CStone Pharmaceuticals, regarding changes in issued shares, treasury shares, and share repurchases. It details share repurchases made on the exchange, with quantities, prices, and confirmation of compliance with exchange rules. There is no financial statement, earnings data, management discussion, or presentation content. The document corresponds exactly to share repurchase disclosures and capital structure updates. According to the classification rules, such detailed capital structure activity and repurchase transaction disclosures are classified under Transaction in Own Shares (POS). The document length and detailed transactional data confirm this is not a short report publication announcement but an actual regulatory disclosure about repurchases and capital changes.
2026-06-17 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return filed under rules governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. It details changes in issued shares and treasury shares, specifically covering share repurchases and cancellations, with specific dates, number of shares, and prices involved. The content strictly involves reporting of transactions in the company's own shares (share buybacks/repurchases) and related confirmations. This fits the description for Transaction in Own Shares filings, which deal with company buybacks or sales of its own shares. The document does not present financial results, board changes, or voting outcomes, nor is it a simple announcement or certification. The length and detail indicate it is a full report of such transactions rather than a short report publication announcement. Hence, the appropriate filing category is Transaction in Own Shares (POS).
2026-06-16 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is titled as a "SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE ANNUAL GENERAL MEETING" and discusses details related to the proposed grants of share options and RSUs to a director and CEO, including voting requirements and shareholder interests. It references an AGM Circular dated 1 June 2026. This document supplements the AGM Circular and provides additional information for shareholder consideration regarding resolutions at the AGM. It is not the AGM circular itself, nor the AGM presentation; it is an announcement related to the AGM materials about share grants for executives. The content focuses on governance and shareholder resolutions for approval at the AGM. Based on the filing definitions, announcements containing materials shared during an AGM or closely related to AGM resolutions fall under "AGM Information (AGM-R)". The document length being over 7,000 characters also supports it being substantive. Therefore, the best classification is AGM Information (AGM-R).
2026-06-16 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a regulatory filing submission titled "Next Day Disclosure Return" from CStone Pharmaceuticals, dated 15 June 2026. The content details changes in issued shares and treasury shares, specifically disclosing a share repurchase (buyback) event. It references specific listing rules on The Stock Exchange of Hong Kong Limited for disclosure of share repurchases and changes in issued shares. The document provides numeric data on shares repurchased, prices, mandates, and compliance confirmations. There are no financial statements, earnings data, or management commentary typical of quarterly or annual reports, nor is this a voting result, AGM material, or legal update. This type of disclosure on share buyback activity aligns precisely with a "Transaction in Own Shares" filing category, as it reports on the company's repurchase of its own shares on the market. Therefore, the document should be classified as POS (Transaction in Own Shares). Given the specificity of the content and regulatory context, confidence is high.
2026-06-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.